

Publications by NovaMatrix (1995 →)

- Aspden, T.J., Adler, J., Davis, S.S., Skaugrud, Ø. and Illum, L.
Chitosan as a nasal delivery system: Evaluation of the effect of chitosan on mucociliary clearance rate in the frog palate model., *Int. J. Pharm.*, **122**, 69-78, (1995).
- Aspden, T.J., Illum, L. and Skaugrud, Ø.
Chitosan as a nasal delivery system: Evaluation of insulin absorption enhancement and effect on nasal membrane integrity using rat models., *Eur. J. Pharm. Sci.*, **4**, 23-31, (1996).
- Aspden, T.J., Mason, J.D.T., Jones, N.S., Lowe, J., Skaugrud, Ø., and Illum, L.
Chitosan as a nasal delivery system: The effect of chitosan solutions on *in vitro* and *in vivo* mucociliary transport rates in human turbinates and volunteers., *J. Pharm. Sci.*, **86**, 509-513, (1997).
- Melvik, J.E., Brekka, G. and Dornish, M.
The determination of the degree of acetylation of chitosan salts., In: *Chitin Handbook*, eds., Muzzarelli, R.A.A. and Peter, M.G., European Chitin Society, Atec, Grottammare, Italy, 1997, pp. 121-125.
- Dornish, M., Hagen, A., Hansson, E., Pecheur, C., Verdier, F. and Skaugrud, Ø.
Safety of PROTASAN™: Ultrapure chitosan salts for biomedical and pharmaceutical use., In: *Advances in Chitin Science*, Vol II, eds. Domard, A., Roberts, G.A.F. and Vårum, K.M., Jacques Andre Publisher, Lyon, France, 1997, pp. 664-670.
- Dornish, M., Skaugrud, Ø., Illum, L. and Davis, S.S.
Nasal drug delivery with PROTASAN™., In: *Advances in Chitin Science*, Vol II, eds. Domard, A., Roberts, G.A.F. and Vårum, K.M., Jacques Andre Publisher, Lyon, France, 1997, pp. 694-697.
- Skaugrud, Ø., Hagen, A., Borgersen, B. and Dornish, M.
Biomedical and pharmaceutical applications of alginate and chitosan., *Biotechnology and Genetic Engineering Reviews*, **16**, 23-40, (1999).
- Holme, H.K., Hagen, A. and Dornish, M.
Influence of chitosans with various molecular weights and degrees of deacetylation on the permeability of human intestinal epithelial cells (Caco-2)., In: *Chitosan per os: from dietary supplement to drug carrier*, ed. Muzzarelli, R.A.A., Atec, Grottammare, Italy, 2000, pp. 127-136.
- Holme, H.K., Foros, H., Pettersen, H., Dornish, M. and Smidsrød, O.
Thermal depolymerization of chitosan chloride., *Carbohydrate Polymers*, **46**, 287-294, (2001).
- Howling, G.I., Dettmar, P.W., Goddard, P.A., Hampson, F.C., Dornish, M. and Wood, E.J.
The effect of chitin and chitosan biopolymers on the proliferation of human skin fibroblasts and keratinocytes *in vitro*., *Biomaterials*, **22**, 2959-2966, (2001).
- Dornish, M., Kaplan, D. and Skaugrud, Ø.
Standards and Guidelines for Biopolymers in Tissue Engineered Medical Products – ASTM Alginate and Chitosan Standard Guides., *Ann. N.Y. Acad. Sci.*, **944**, 388-397, (2001).
- Kristiansen, A, Holme, H.K., Leth-Olsen, K.-A. and Vedaa, I.
Thermal properties of some chitosans and chitosan salts. In: *Chitin and Chitosan in Life Science*, eds. Uragami, T., Kurita, K. and Fukamizo, T., Kodansha Scientific Ltd. Tokyo, Japan, 2001, pp. 51-54.
- Howling, G.I., Dettmar, P.W., Goddard, P.A., Hampson, F.C., Dornish, M., and Wood, E.J.
The effect of chitin and chitosan on fibroblast-populated collagen lattice contraction., *Biotechnol. Appl. Biochem.*, **36**, 1-6, (2002).
- Klokk, T.I. and Melvik, J.E.
Controlling the size of alginate gel beads by use of a high electrostatic potential., *J. Microencapsulation*, **19**, 415-424, (2002).
- Kristiansen, A, Holme, H.K., Isaksen, M., Leth-Olsen, K.-A. and Vedaa, I.
Thermal decomposition of chitosan chlorides. In: *Advances in Chitin Science*, Vol VI, eds. Vårum, K.M., Domard, A. and Smidsrød, O., Tapir Trykk, Trondheim, Norway, 2003, pp. 111-114.
- Holme, H.K., Lindmo, K., Kristiansen, A. and Smidsrød, O.
Thermal depolymerization of alginate in the solid state., *Carbohydrate Polymers*, **54**, 431-438 (2003).

Publications by NovaMatrix (1995 →)

- Smith, J.M., Wood, E. J. and Dornish, M.,
Effect of chitosan glutamate on epithelial tight junctions, *Adv. Chitin Science*, **6**, 283-284, (2003).
- Sasaki, C., Kristiansen, A. and Vårum, K.M.,
Biospecific fractionation of chitosan, *Biomacromolecules*, **4**, 1686-1690, (2003).
- Holte, O., Onsoyen, E., Myrvold, R. and Karlsen, J.,
Sustained release of water-soluble drug from directly compressed alginate tablets, *Eur. J. Pharm. Sci.*, **20**, 403-407, (2003).
- Bjerkvig, R., Read, T-A., Vajkoczy, P., Aebischer, P., Pralong, W., Platt, S., Melvik, J.E., Hagen, A., and Dornish, M.,
Cell therapy using encapsulated cells producing endostatin, *Acta Neurochir.*, **88 [Suppl]**, 137-141, (2003).
- Marshall, P., Snaar, J.E., Ng, Y.L., Bowtell, R.W., Hampson, F.C., Dettmar, P.W. Onsoyen, E. and Melia, C.D.,
Localised mapping of water movement and hydration inside a developing bioadhesive bond, *J. Controlled. Release*, **95**, 435-436, (2004).
- Dornish, M. and Dessen, A.,
Alginate and Chitosan Standards for Tissue Engineered Medical Products. In: *Tissue Engineered Medical Products (TEMPS)*, *ASTM STP 1452*, E. Schutte, G.L. Picciolo and D.S. Kaplan, Eds., ASTM International, West Conshohocken, PA; pp. 137-149, (2004).
- Melvik, J.E. and Dornish, M.,
Alginate as a carrier for cell immobilisation, In: V Nedovic and R Willaert (eds), *Fundamentals of Cell Immobilisation Biotechnology*, Kluwer; pp. 33-51, (2004).
- Smith, J., Wood, E. and Dornish, M.,
Effect of chitosan on epithelial cell tight junctions, *Pharm. Res.*, **21**, 43-49, (2004).
- Dornish, M. and Kaplan, D.,
Regulatory aspects and standardization of chitin and chitosan, *Adv. Chitin Science*, **7**, 152-156, (2004).
- Dornish, M., Melvik, J.E., Bjerkvig, R., Vajkoczy, P., Pralong, W. and Platt, S.,
Sustained release of endostatin from alginate-encapsulated producer cells, Abstract 157, Podium presentation, 2004 Controlled Release Society Annual Meeting, (June 2004).
- Smith, J.M., Dornish, M. and Wood, E.J.,
Involvement of protein kinase C in chitosan glutamate-mediated tight junction disruption, *Biomaterials* **26**, 3269-3276 (2005)
- Michael Dornish and Frank Rauh, Alginate, In: *An Introduction to Biomaterials*, S.A. Guelcher and J. O. Hollinger (eds), CRC Press, Boca Raton FL; pp. 261-272 (2006).
- Frank Rauh and Michael Dornish, Chitosan, In: *An Introduction to Biomaterials*, S.A. Guelcher and J. O. Hollinger (eds), CRC Press, Boca Raton FL; pp. 249-260 (2006).

**NovaMatrix
FMC BioPolymer**

Technical Assistance
& Customer Service: +1 215 299 6453
Fax: +1 215 299 6669
E-Mail: novamatrix_info@fmc.com

Order Center: +47-32203551
Fax: +47-32203510
E-Mail: novamatrix_info@fmc.com

U.S.A.:

1735 Market Street
Philadelphia PA 19103
USA

Norway:

Gaustadalléen 21
N-0349 Oslo
Norway
Tel.: +47 2295 8650
Fax: +47 2269 6470
E-Mail: novamatrix_info@fmc.com

Patents

NovaMatrix/FMC Corporation does not warrant against infringements of patents of third parties by reason of any uses made of the product in combination with other material or in the operation of any process, and purchasers assume all risks of patent infringement by reason of any such use, combination, or operation.

Warranty

Because of the numerous factors affecting results, NovaMatrix/FMC products are sold under the understanding that purchasers will make their own tests to determine the suitability of these products for their particular purpose. The several uses suggested by NovaMatrix/FMC Corporation are presented only to assist our customers in exploring possible applications. All information and data presented are believed to be accurate and reliable, but are presented without the assumption of any liability by NovaMatrix/FMC Corporation.

Technical Service

The information contained in this bulletin is intended to be general in nature. Techniques and data pertaining to specific uses for NovaMatrix/FMC products and new developments will be published periodically in the form of supplemental application bulletins. Our technical staff is ready to offer assistance in the use of NovaMatrix/FMC products.

Regulatory Status

PRONOVA™ sodium alginate meets the standards set forth in the current editions of the United States Pharmacopeia/National Formulary and European Pharmacopoeia. PROTASAN™ chitosan chloride meets the standard set forth in the European Pharmacopoeia. Sodium Hyaluronate Pharma Grade meets the standard set forth in the European Pharmacopoeia. PRONOVA™ sodium alginate, PROTASAN™ chitosan salts and Sodium Hyaluronate Pharma Grade satisfy the requirements for use in tissue-engineered medical products as set forth in ASTM F2064, ASTM F2103 and ASTM F2347, respectively. PRONOVA™ sodium alginate, PROTASAN™ chitosan products and Sodium Hyaluronate Pharma Grade are manufactured in compliance with current Good Manufacturing Practice and described in separate DMF's submitted to the US FDA.

Visit our web site at www.novamatrix.biz

NovaMatrix, FMC BioPolymer PROTASAN
and PRONOVA are trademarks of FMC
Corporation.
©2002 FMC Corporation
All rights reserved

